Mr. Lubniewski assumes the role after having served for seven years as Chief Business Officer
What drives the excitement in ImmunoOncology? Qiagen asked John Lubniewski, of HTG Molecular Diagnostics. (Recorded by Qiagen at ASCO17)
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the promotion of John Lubniewski to President and Chief Operating Officer. Mr. Lubniewski has served as HTG’s chief business officer for the past seven years, bringing over three decades of experience in the life science industry.
“We warmly congratulate John on his well-deserved promotion to President and Chief Operating Officer,” said TJ Johnson, Chief Executive Officer of HTG. “John is a dynamic member of our team and widely respected in our industry. Over the last seven years, John has consistently demonstrated his capabilities and value to HTG, which will continue to serve him well in his new role as President, as he optimizes HTG’s operations for its continued growth.”
Mr. Lubniewski added, “I am thrilled to be working in the role of President with the team here at HTG. Our team has proven to be focused on growth and driven to succeed, and I am very motivated to build on our successes to date.”
Mr. Lubniewski has served as our Chief Business Officer since April 2011. He joined HTG from Ventana, a medical diagnostics company and member of the Roche Group and global headquarters of Roche Tissue Diagnostics, or RTD. During his time at Ventana, Mr. Lubniewski served in several senior leadership roles and was responsible for marketing and global accountability for all clinical assay products. Prior to the acquisition by Roche, Mr. Lubniewski was responsible for a variety of assay and platform development and commercialization efforts across the company. Prior to Ventana, Mr. Lubniewski spent over a decade working at Corning, Inc., a manufacturing company, in a variety of roles including divisional, sector, and corporate sales, and marketing roles. Mr. Lubniewski earned a B.S. in Chemical Engineering from Clarkson University.
About HTG
HTG is focused on next generation sequencing (NGS) based molecular profiling. The company’s proprietary HTG EdgeSeq technology automates complex, highly multiplexed molecular profiling from solid and liquid samples, even when limited in amount. HTG’s customers use its technology to identify biomarkers important for precision medicine, to understand the clinical relevance of these discoveries, and ultimately to identify treatment options. Our mission is to empower precision medicine at the local level.
Safe Harbor Statement
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the benefits and uses of our patented technologies, and the size, expiration date(s) and content of our patent portfolio, each patent of which is subject to timely annuity fee payments, will expire as a matter of course even if annuities are timely paid, and may be adversely affected by potential legal challenges prior to its expiration. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based upon management’s current expectations, are subject to known and unknown risks, and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation, our ability to successfully develop, market and/or commercialize new methods, technologies and/or products, including our patented technologies. These and other factors are described in greater detail in our filings with the Securities and Exchange Commission, including without limitation our Annual Report on Form 10‑K for the year ended December 31, 2017. All forward-looking statements contained in this press release speak only as of the date on which they were made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
FOR FURTHER INFORMATION CONTACT:
Ashley Robinson
LifeSci Advisors, LLC
617-775-5956
arr@lifesciadvisors.com
TJ Johnson
President/CEO
HTG Molecular Diagnostics
520-547-2827 x130
tjjohnson@htgmolecular.com